Compare TRVG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | TSHA |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.1M | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | TRVG | TSHA |
|---|---|---|
| Price | $2.81 | $5.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $3.96 | ★ $10.56 |
| AVG Volume (30 Days) | 35.6K | ★ 2.5M |
| Earning Date | 02-03-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $614,486,683.00 | $6,310,000.00 |
| Revenue This Year | $18.55 | N/A |
| Revenue Next Year | $9.78 | N/A |
| P/E Ratio | $94.27 | ★ N/A |
| Revenue Growth | ★ 14.41 | N/A |
| 52 Week Low | $2.55 | $1.05 |
| 52 Week High | $5.83 | $6.02 |
| Indicator | TRVG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 49.69 |
| Support Level | $2.75 | $4.40 |
| Resistance Level | $2.87 | $5.17 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 41.67 | 50.38 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.